Repligen Corporation

NASDAQ:RGEN

Medical - Instruments & Supplies

Healthcare
$172.67 -2.74%

-$3.66 today

Market cap
$11.04B
Beta
1.08
P/E (TTM)
142.4
EPS (TTM)
$0.91
52W Low $100.99High $175.77

Volume 1.30M

Average 1.08M

RGEN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Repligen CorporationNASDAQ: RGEN

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 53.1%

Gross margin was 53.1% in Q2 FY2026, up 3.1 pp from a year earlier. On a trailing-twelve-month basis it was 51.1%, up 6.8 pp year over year. Over 3 fiscal years it narrowed by 9.8 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
53.1%+2.4 pp QoQ
Last fiscal yearDec 2025
47.1%+3.8 pp YoY
LTMJun 2026
51.1%+6.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.1 pp——
1 year+3.8 pp——
3 years-9.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
47.1%
Year-over-year change
+3.8pp

Gross Margin vs competitors

How RGEN compares with its peers on the latest reported figures

  • RGEN's LTM Jun 2026 gross margin of 51.1% is the 6th highest of the 9 companies compared; the peer median is 52.8%.
  • Its year-over-year change of +6.8 pp is the highest of 9, against a peer median of -0.3 pp.
  • Over three fiscal years its change of -9.8 pp compares with a peer median of -2.0 pp.
RGEN Competitors Peer median
Gross Margin for RGEN and competitors
Company Period LTM level YoY 3-year change
TECHBio-Techne CorporationLTM Sep 202665.8% +0.4 pp-2.0 pp
BLFSBioLife Solutions, Inc.LTM Mar 202663.9% -19.5 pp+3.0 pp
QGENQiagen N.V.LTM Jun 202661.8% -1.1 pp-2.9 pp
AAgilent Technologies, Inc.LTM Jul 202653.7% +0.8 pp-1.9 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202651.9% -0.9 pp-3.9 pp
RGENRepligen CorporationLTM Jun 202651.1% +6.8 pp-9.8 pp
TMOThermo Fisher Scientific Inc.LTM Sep 202641.4% +1.0 pp-1.4 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 202634.6% +5.5 pp-62.9 pp
AVTRAvantor, Inc.LTM Jun 202631.8% -1.4 pp-2.0 pp
Peer median (excluding RGEN) 52.8%-0.3 pp-2.0 pp

Competitors are the stored peer set for RGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue670.53M801.54M632.36M634.44M738.26M
Cost of Revenue279.28M345.83M353.92M359.79M390.63M
Gross Profit391.25M455.71M278.44M274.65M347.62M
Gross Margin58.3%56.9%44.0%43.3%47.1%
Research & Development34.27M43.94M42.72M43.2M54.18M
Selling, General & Admin183.87M215.83M218.58M263.37M290.51M
Operating Expenses224.01M231.04M230.74M309.76M288.05M
Depreciation & Amortization38.45M57.01M86.11M86.56M96.96M
EBITDA203.27M277.31M145.32M80.26M182.51M
EBITDA Margin30.3%34.6%23.0%12.7%24.7%
Operating Income167.25M224.67M47.7M(35.11M)59.58M
Operating Margin24.9%28.0%7.5%-5.5%8.1%
Interest Income176K6.98M0027.57M
Interest Expense12.71M2.98M10.03M22.57M23.17M
Other Income / Expenses(13.71M)(5.53M)9M8.08M2.81M
Income Before Tax153.54M219.14M56.71M(27.04M)62.38M
Pre-Tax Margin22.9%27.3%9.0%-4.3%8.5%
Income Tax Expense25.25M33.18M21.11M(1.52M)13.49M
Net Income128.29M185.96M35.6M(25.51M)48.89M
Net Margin19.1%23.2%5.6%-4.0%6.6%
EPS (Basic)2.333.350.64(0.46)0.87
EPS (Diluted)2.243.240.63(0.46)0.86
Weighted Avg Shares55.02M55.46M55.72M55.94M56.23M
Weighted Avg Shares (Diluted)57.26M57.46M56.38M55.94M56.56M

Repligen Corporation

NASDAQ:RGEN

Intrinsic Alpha fair value

Locked

Current Price

$172.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.